Revlimid cliff
Generic Revlimid, or lenalidomide, a blood cancer drug, was a high-margin US product for Indian drugmakers until early 2026. Under patent settlements with the brand’s owner, several companies, including Dr. Reddy’s, Cipla, Zydus and Aurobindo, began selling limited volumes in 2022. These volume restrictions ended on 31 January 2026, paving the way for new manufacturers, including Intas’s Accord Healthcare.















Leave a Reply